Abstract 1833
Background
Although the personalized medicine has always focused on the genomic or proteomic characterization of tumor, medical imaging is still one of the major factors to guide therapy and to monitor the progression of the tumor. Radiomics is an emerging field that converts the medical image data into the mineable quantitative features via the automatically algorithms, and can server as a bridge between medical image, genomics and clinical-parameters. Serval studies have demonstrated that the radiomic-based model can predict outcome of RCC, but the correlation between radiomic features and histological subtypes of RCC is still unknown. The aim of this letter is to focus on the ability of radiomics to identify the histological subtypes and metastasis of RCC.
Methods
This study included Forty-four patients diagnosed with renal tumor. For each renal lesion, The CT images of volume of interest (VOI) were obtained semi-automatically by two experienced nuclear medicine physician, 85 texture features were extracted from each VOI using the first-order statistics features, Shape Based Features, Gray Level Neighboring Gray Level Dependence Matrix and Neighboring Gray Tone Difference Matrix.
Results
To investigate the value of radiomic features to capture phenotypic differences of RCC, we performed Unsupervised Clustering of patients with similar radiomic expression patterns. We analyzed the two main clusters of patients with clinical parameters, and found that the tumor clusters were statistically and significantly associated with primary tumor stage (P < 0.001), M-stage (P = 0.049) and benign (P = 0.037), wherein high T-stages, M-stage and tumor group showed in cluster II. RCC histology and N-stage (lymph-node) did not reach statistical significance for their association with the radiomic expression patterns (P = 0.165, 0.361, respectively). In addition, we analyzed the overall survival (OS) of the each radiomic features, and showed that P25, IMC1 and IMC2 were associated with OS (P = 0.002, 0.002, 0.016, respectively, log-rank test).
Conclusions
The radiomic features from medical images could be helpful in deciphering T-stages, metastasis and benign of RCC and may have potential as imaging biomarker for prediction of RCC overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
National Natural Science Foundation of China (No 81402117, 81671775), Natural Science Foundation of Zhejiang Province (No LY17H160043) and Qianjiang talent plan of Zhejiang Province (No QJD1602025).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract